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CHAPTER 1. INTRODUCTION 
Myocardial stunning is the postischemic mechanical dysfunction of the heart that 
persists after reperfusion despite the absence of irreversible damage. It was first 
recognized as an experimental entity in 1975 (Heyndrickx et al ). The realization that this 
phenomenon has clinical relevance resulted in an enormous increase in research devoted to 
its pathogenesis, pathophysiology, and therapy in the past decade. 
It is important to distinguish stunned myocardium from hibernating myocardium. 
Hibernating myocardium is a persistant contractile dysfunction that is associated with 
reduced coronary flow but preserved myocardial viability (Bolli, 1992). Myocardial 
hibernation is believed to be an adaptive response by which the cell downregulates its 
oxygen demand in response to a reduced oxygen supply in order to maintain viability. 
These cells show no metabolic evidence of ischemia (Rahimtoola, 1989). It is believed 
that myocardial stunning, hibernation, and silent ischemia may frequently coexist (Bolli, 
1992). 
Myocardial stunning becomes clinically important during any situation in which the 
myocardium is subjected to transient ischemia (Bolli, 1992). Clinical settings in which 
this may occur include; unstable or variant angina, acute myocardial infarction with early 
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reperfusion (either spontaneously or via thrombolytic therapy), open heart surgery with 
cardioplegic arrest, percutaneous transluminal coronary angioplasty, or cardiac 
transplantation. Myocardial stunning associated with these procedures may significantly 
contribute to their morbidity and mortality because of the temporary inability of the heart 
to maintain adequate hemodynamic parameters. 
Standard therapy for a stunned myocardium currently involves the use of inotropic 
or after-load reducing agents, an intra-aortic balloon pump, maintenance on a 
cardiopulmonary bypass machine, or use of an artificial left ventricular assist device 
(LVAD) (Grooters, 1991). Positive inotropes have been shown, both experimentally and 
clinically, to induce a dramatic functional recruitment in stunned myocardial tissue. What 
has not been shown is whether their long term administration causes any significant 
detrimental effects in stunned tissue. Known effects of positive inotropes in myocardial 
tissue include their potential to induce arrhythmias and to also cause an increase in 
myocardial oxygen consumption. The latter effect may be disadvantageous in patients 
with coexisting myocardial hibernation (Bolli, 1992). 
The intra-aortic balloon pump is frequently used as an after-load reducing device 
and is capable of increasing cardiac output up to 20 percent. These devices are limited in 
their effectiveness because they cannot augment cardiac pressure development. LVADs 
are employed with clinical cases in which pharmacological and intra-aortic balloon therapy 
are ineffective (Grooters, 1991). These devices require extensive surgical procedures for 
both placement and removal, high level anticoagulant therapy, and they are difficult to 
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maintain. 
Ronald K. Grooters, M.D., a cardiac surgeon at Iowa Methodist Medical Center, 
1200 Pleasant Street, Des Moines, Iowa, patented an idea for a direct, systolic ventricular 
assist device in 1991. The idea for the device originated from clinical experiences with 
postischemic dysfunctional hearts. Dr. Grooters subjectively felt that these hearts would 
fully contract when given only partial assistance during direct cardiac massage. The 
original description of the device consisted of two distensible balloons, each directly 
adjacent to a ventricle, which were held in position by a nondistensible shell or sac that 
encompassed the heart. Inflation of the balloons would be ^nchronized with ventricular 
systole by using a cardiac electrical signal. The device could be easily ^plied or 
removed from the heart and held in place by being tethered to the ascending aorta. 
A feasibility study for such a device was performed at Iowa State University, 
Ames, Iowa, under the direction of Donald F. Young, Ph.D.. Details of the design, 
development, construction, and initial testing of the device have been previously described 
(Frake, 1992). The current study involves an evaluation of the device when applied to an 
experimental model of a heart with global postischemic dysfunction. 
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CHAPTER 2. LITERATURE REVIEW 
Myocardial stunning 
Description. Myocardial stunning, or postischemic ventricular dysfunction, is 
the mechanical dysfunction that persists after reperfusion despite the absence of 
irreversible damage (Bolli, 1990a). The dysfunctional tissue involved in myocardial 
stunning is completely viable and has the potential to regain its full normal function. 
Although the development of myocardial stunning and infarction may share some similar 
events, the two conditions are clearly distinct. Myocardial stunning is a sublethal tissue 
injury. 
The classical model for myocardial stunning is produced after one completely 
reversible ischemic episode. In a dog, ligating a coronary artery for less than 20 minutes 
does not result in any myocardial necrosis, but it does produce prolonged contractile 
dysfunction (Jennings and Reimer, 1983; Kioner et al., 1983). Ligation of the left anterior 
descending coronary artery in the dog for a period of 15 minutes produces one of the most 
commonly used experimental models for myocardial stunning (Bolli, 1990a; Pruess et al., 
1987). 
The severity of myocardial stunning appears to be related to the severity and 
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duration of the ischemic event which preceded the injury. The endocardial layers of the 
left ventricle are more severely affected than the epicardial layers in a stunned 
myocardium because they are more severely ischemic as a result of the transmural 
direction of blood flow (Bolli et al., 1989c). It has also been shown that the longer the 
duration of the ischemic episode, the more pronounced the contractile dysfunction (Preuss 
et al., 1987). This correlation suggests that ischemia is the initiating and controlling factor 
in the development of a stunned myocardium. Although the major contribution to the 
cellular injury in this syndrome appears to occur at the time of reperfusion, the preceding 
ischemic period apparently sets the stage for it. Any reduction in the severity of ischemia 
will attenuate the severity of the stunning that appears after reperfusion. 
Mechanism of development. Several mechanisms have been proposed to explain 
the development of myocardial stunning. The exact sequence of events, which begins 
during ischemia and is apparently completed at the time of reperfusion, is not completely 
understood. The relative contribution, if any, from each of these proposed mechanisms 
towards the development of a stunned myocardium is speculative. 
The major mechanisms currently proposed for myocardial stunning are: 
* Generation of oxygen-derived free radicals 
* Calcium overload 
* Excitation-contraction uncoupling due to sarcoplasmic reticulum dysfunction 
Generation of oxvpen-derived free radicals. The proposal that the generation 
of oxygen-derived free radicals was responsible, in part, for the development of a stunned 
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myocardium was originally investigated by the comparative use of antioxidants during 
experimental modeling (Bolli, 1990a). These experiments were generally concerned with 
the generation of the following reactive oxygen metabolites; superoxide anion (O;-), 
hydrogen peroxide (HjOj), and the hydroxyl radical (OH). Studies involving the 
administration of super oxide dismutase (SOD), an enzyme which catalyzes the 
dismutation of superoxide anion (0%-) to 0% and HjOj, and catalase, an enzyme which 
reduces H^O; to 0% and H^O, showed that they significantly enhanced the recovery of the 
stunned model during the post-reperfusion period (Myers et al., 1985; Murry et al., 1989). 
It was found that neither SOD or catalase, when used alone, significantly improved the 
functional recovery of the stunned myocardium. These results suggest that both of the 
reactive oxygen metabolites, superoxide anion and hydrogen peroxide, may be involved in 
myocardial stunning. 
Because superoxide anion and hydrogen peroxide are able to react, via the metal-
catalyzed Haber-Weiss reaction, and form the very reactive hydroxyl radical, it is 
unknown to what extent they each cause direct cytotoxicity (Halliwell and Gutteridge, 
1984). Hydroxyl radical scavengers, dimethylthiourea and N-2-mercaptopropionyl glycine 
(MPG), have each been shown to not interact with superoxide anion or hydrogen peroxide 
and to attenuate the dysfunction associated with stunning (Bolli et al., 1987b; Bolli et al., 
1989a). These findings suggest that the hydroxyl radical, or a product thereof, is involved 
in myocardial stunning. This is supported by data which shows that the iron chelator, 
desferrioxamine, has an attenuating effect on stunning. This would theoretically be by 
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inhibiting the iron catalyzed Haber-Weiss reaction (Bolli et al., 1987a; Farber et al., 1988). 
Because superoxide anion has been shown to be directly cytotoxic, it seems apparent that 
all of the reactive species mentioned have a role in the development of postischemic 
dysfunction, with superoxide anion and hydroxy! radical as mediators of injury and 
hydrogen peroxide as a precursor of the hydroxyl radical (Schrier and Hess, 1988). 
The production of free radicals during experimental modeling of a stunned 
myocardium has been demonstrated by use of the spin trty) alpha-phenyl N-tert-butyl 
nitrone (PBN) and electron paramagnetic resonance (EPR) spectroscopy (Bolli et al., 
1988a). After the infusion of PBN, the venous blood draining the ischemic-reperfused 
myocardium showed EPR signals consistent with a mixture of different secondary lipid 
radicals, such as alkyl and alkoxy radicals. The myocardial production of these radicals 
increased dramatically, peaked at 2 - 4 minutes, and persisted for as long as 3 hours after 
reperfusion (Bolli et al., 1988a). In this study, there was a direct, linear relationship 
between the degree of flow reduction to the ischemic area and the amount of radicals 
produced. Further studies have shown a decrease in free radical production and 
attenuation of dysfunction with the use of SOD and catalase, MPG, and desferrioxamine 
(Bolli et al., 1989a; Bolli et al., 1989b). This seems to indicate that the reduction of 
oxygen is the cause of free radical production in canine models of a stunned myocardium 
and that free radical reactions are necessary for postischemic dysfunction to occur (Bolli, 
1990a). 
How oxygen metabolites result in the damage which occurs during myocardial 
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stunning is unresolved. Free radicals can attack virtually eveiy cellular component. They 
can denature proteins, inactivate enzymes, and produce peroxidation of the 
polyunsaturated fatty acids contained in cellular membranes (Davies, 1987; Thompson and 
Hess, 1986). An increased concentration of hydroxy conjugated dienes, which are 
products of free fatty acid oxidation, has been found in the post-reperfusion myocardium 
of dogs which had undergone a period of global ischemia (Romaschin et al., 1987) and in 
the coronaiy sinus of patients which had undergone cardioplegic arrest during bypass 
surgery (Weisel et al., 1989). 
The sarcoplasmic reticulum (SR) and the sarcolemma appear to be critical targets of 
free radical damage. Calcium uptake by the sarcoplasmic reticulum and Ca^^,Mg^^-
ATPase activity are each depressed in the stunned myocardium (Krause et al., 1989). 
Similar effects are seen after the exposure of isolated SR to oxygen radicals, with free 
radical scavengers preventing this injury (Thompson and Hess, 1986; Rowe et al., 1983). 
Oxyradicals have also been shown to interfere with sarcolemmal calcium pump activity, 
Na^-Ca^^ exchange, and Na^K^-ATPase activity (Kaneko et al., 1989a; Kaneko et al., 
1989b; Reeves et al., 1986; Kramer et al., 1984). The impairment of Na^,K*-ATPase 
activity has been demonstrated in reperfused myocardial tissue and is prevented by 
antioxidants (Kim and Akera, 1987). Because the impairment of Na^-K^ exchange would 
increase the activity of the Na^-Ca^^ exchange mechanism, each of these documented 
effects of free radical injury would lead to an increase in the cytoplasmic calcium levels 
and could potentially result in cellular calcium overload, which is another proposed 
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contributor to postischemic ventricular dysfunction. 
Potential sources for the production of oxygen-derived free radicals in myocardial 
stunning include the enzyme xanthine oxidase and activated neutrophils. Allopurinol, a 
xanthine oxidase inhibitor, produced a significant improvement in the recovery of 
experimentally stunned dog hearts (Charlat et al., 1987). Because there is a marked 
species difference in the myocardial content of xanthine oxidase, the extent to which 
xanthine oxidase contributes to myocardial stunning in humans is uncertain. Leukocytes 
are another potential source of oxyradicals, but their role in irreversible injury after 
prolonged ischemia appears to be greater than their role in myocardial stunning (Engler, 
1987; Shea et al., 1987; O'Neill et al., 1989). 
Other potential sources for the production of oxygen-derived free radicals include 
activation of the arachidonate cascade, autoxidation of catecholamines and other 
compounds, ischemia-induced damage of the electron transport chain, and accumulation 
of reducing equivalents (Thompson and Hess, 1986). 
A comparison of the effects seen with the use of antioxidants, either before or during 
reperfusion after short periods of ischemia, has suggested that most of the cellular damage 
which occurs during myocardial stunning takes place within the first few moments of 
reperfusion. Antioxidants are protective if given before reperfusion, but they become 
ineffective if given more than a minute after reperfusion (Bolli et al., 1989a). The direct 
measurement of free radicals and the measurement of lipid peroxidation products show a 
large increase or burst during the initial moments after reperfusion (Bolli et al., 1989a; 
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Bolli et al., 1988a; Bolli et al, 1989b; Romaschin et al., 1987). These findings suggest 
that myocardial stunning is, in part, an oxyradical-mediated injury which occurs at the 
time of reperfusion. 
Calcium overload. Calcium overload has also been implicated as a 
contributing factor in the development of postischemic ventricular dysfunction. 
Experimental evidence in support of this proposal includes the attenuation of postischemic 
dysfunction in isolated ferret hearts when they are reperfused with solutions containing 
low concentrations of calcium (Kusouka et al., 1987). Attenuation of stunning has also 
been shown in hearts which are pretreated with ryanodine, an agent which blocks the 
calcium release channel of the sarcoplasmic reticulum (Porterfield et ai., 1987). Induced 
transient calcium overload in perfused ferret hearts has been shown to produce functional 
and metabolic abnormalities similar to those found in stunned myocardium (Kitakaze et 
al., 1988b). A transient intracellular acidosis, which inhibits the Na+-Ca2+ exchange and 
the slow calcium channels, can prevent stunning during early reperfusion in ferrets and 
dogs (Kitakaze et al., 1988a; Hori et al., 1989). 
The intracellular concentration of calcium has been shown to increase early in 
myocardial ischemia (between 10 and 20 minutes). It remains transiently elevated 
immediately following reperfusion and returns to normal values within a few minutes 
after reperfusion (Steenbergen et al., 1987; Kitakaze et al., 1988b). Possible mechanisms 
for the rise in the intracellular calcium concentration during ischemia include a decreased 
uptake by the SR (Krause and Hess, 1984) or activation of the Na+-Ca2+ exchange 
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mechanism secondary to an increase in intracellular Na+ from either the metabolic 
inhibition of the Na+,K+-ATPase or the activation of the Na+-H+ exchange mechanism 
due to cellular acidosis (Murphy et ai., 1988; Tani and Neely, 1989). The damaging 
increase in the intracellular calcium concentration associated with the calcium overload 
theory is postulated to briefly occur immediately after reperfusion. Because the Na^-Ca^^ 
exchange is inhibited by acidosis, this exchange may be greatly increased with the 
normalization of the intracellular pH immediately following reperfusion (Kusouka et al., 
1987; Tani and Neely, 1989). 
How the calcium overload mediates a prolonged contractile dysfunction remains 
uncertain. Increased cytosolic calcium levels can activate phospholipases and other 
degradative enzymes and may also cause the formation of oxygen-derived free radicals 
via xanthine oxidase (Marban et al., 1989; McCord, 1985). Although the calcium channel 
blockers have been shown to improve recovery in the postischemic period, because their 
beneficial effects are still present when initiated 30 minutes post-reperfusion, their direct 
benefit to myocardial contractile function is speculative (Przyklenk et al., 1989). 
Excitation-contraction uncoupling due to SR dvsfunction. A decrease in the 
ability of the sarcoplasmic reticulum to transport calcium and a reduction in Ca^^,Mg^^-
ATPase activity were found after eight to twelve 5-minute occlusions of the left anterior 
descending coronary artery in the dog. Each occlusion was followed by a 10 minute 
period of reflow (Krause et al., 1989). This finding led to the conclusion that the inability 
of the SR to store calcium may result in an inadequate release during systole resulting in 
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excitation-contraction uncoupling. This mechanism of dysfunction would be consistent 
with the finding that both exogenous calcium administration and inotropic agents, which 
increase intracellular calcium concentrations, can reverse myocardial stunning (Ellis et al., 
1984; Bolli et al., 1985; Ito et al., 1987; Ambrosio et al., 1987). However, the implication 
that the intracellular calcium transient is decreased after reperfusion is not consistent with 
other research data (Kusuoka et al., 1990; Guamieri, 1989). 
Other possible mechanisms. Other mechanisms have been proposed for 
myocardial stunning, but they are not believed to be as likely to contribute to postischemic 
contractile dysfunction as the three which have been discussed. These other mechanisms 
will be only briefly discussed. 
Insufficient energy production by the mitochondria has been proposed as a 
mechanism because ATP levels are decreased during the post-reperfusion period and they 
gradually increase while the contractile function is also increasing (Kloner et al., 1983; 
Swain et al., 1982). However, other research data which are inconsistent with this 
proposal include: the lack of correlation between ATP levels and function in other models 
(Kusouka et al., 1987; Neely and Grotyohann, 1984), the normal or supranormal content 
of phosphocreatine in stunned myocardium (Kusouka et al., 1987; Ambrosio et al., 1987), 
a striking contractile reserve demonstrated by the response of stunned myocardial tissue to 
inotropic agents without a decrease in ATP levels (Ambrosio et al., 1987; Ellis et al., 
1984; Ito et al., 1987), and the lack of contractile response to increases in intracellular 
ATP levels (Ambrosio et al., 1989). 
The impaired use of energy by the myofibrils was proposed because of the reduction 
in stunned myocardium of myofibrillar creatine kinase activity and of free ADP, the 
substrate used by creatine kinase at the contraction site to produce ATP (Ambrosio et al., 
1987; Greenfield and Swain, 1987). This proposal is inconsistent with the demonstration 
of the contractile reserve in response to inotropic stimulation (Ambrosio et al., 1987; Ellis 
et al., 1984; Ito et al., 1987). 
The loss of sympathetic neural response was noted after 25 minutes of coronary 
occlusion in the dog (Ciuffo et al., 1985), but it was not lost after a 15 minute occlusion. 
(Heush et al., 1988) This proposed mechanism may play a role in myocardial infarction, 
but it has not been demonstrated in models of myocardial stunning (Bolli, 1990a). 
A slight decrease in subendocardial blood flow has been documented in models of 
stunned myocardium (Bolli et al., 1988b; Bolli et al., 1989c; O'Neill et al., 1989; Bolli et 
al., 1990b). This mechanism is not believed to be a primary cause of myocardial stunning 
because of the lack of correlation between subendocardial blood flow and wall thickening 
(Bolli et al., 1990b), the lack of proportion between the significant loss of function and 
the slight decrease (approximately 20%) in subendocardial perfusion (Bolli et al., 1990b), 
and the significant contractile reserve present in the stunned myocardium (Ito et al., 1987). 
The proposal that damage to the extracellular collagen matrix may be a contributing 
factor to myocardial stunning has not been supported by experiments involving one 15-
minute coronary occlusion (Whittaker et al., 1989). Also, the time course of contractile 
recovery during reperfusion of a stunned heart is much too short (with most of the 
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recovery occurring within the first 3 to 4 hours of reperfusion) for there to be any 
significant repair of damaged protein (Bolli et ai., 1988b; Preuss et ai., 1987). 
Another proposal for the mechanism of contractile dysfunction during stunning is 
that there is a decrease in the sensitivity of the myofilaments to calcium (Kusouka et al., 
1987). Evidence which apparently disputes this proposal is that there is a normal 
contractile response, in vivo, to exogenous calcium and other inotropic agents (Ito et al., 
1987). 
Previous assist devices 
There have been numerous designs for devices which provide direct mechanical 
ventricular assistance (Vineberg, 1957; Wolcott et ai., I960; Kline, 1962; Kolobow and 
Bowman, 1965; Zajtchuk et al., 1966; Anstadt et al., 1966). Their designs and the results 
from initial testing have been previously described (Frake, 1992). Of all these devices, 
the one which has received the most attention and has recently been evaluated in a clinical 
feasibility trial for refractory cardiac arrest patients is the Anstadt cup (Anstadt et al., 
1991). A brief description of the Anstadt device follows. 
The Anstadt cup consists of an outer glass housing which roughly approximates the 
diastolic shape of the heart. The housing is less conically shaped than the heart at the 
apex and narrows slightly at the base. An internal polyurethane diaphragm is bonded to 
the glass housing at the apex and at the base or inlet. This diaphragm also flares inward 
at the inlet to form a ventricular sealing rim which approximates the atrioventricular 
groove when the device is applied to the heart. The device is activated by alternately 
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applying positive (systole) and negative (diastole) air pressure into the space between the 
diaphragm and the glass housing. When pressurized, the diaphragm assumes an hourglass 
shape which circumferentially compresses the ventricles. The device is maintained on the 
heart by a sustained negative pressure ;^)plied to the epicardial surface through the apex of 
the housing. The ventricular sealing rim assists in maintaining a continuous negative 
pressure between the heart and the assist device. 
The Anstadt device has been shown to provide adequate total circulatoiy support 
with minimal damage to the myocardium. In an article which reviews the physiological 
effects of the Anstadt device during ventricular fibrillation in dogs (Skinner et al., 1967), 
mean arterial pressures greater than 75 mmHg were consistently reported in animals which 
were supported for 24 hours or more. Cardiac outputs were reported to achieve an overall 
average which reached 49 percent of control levels and regional blood flow was found to 
be adequate to all vital organs. Arterial pH in animals given total circulatory support for 
6 to 24 hours was found to generally remain within physiologic levels and to be similar to 
control animals which had undergone anesthesia and thoracotomy. Coronary sinus blood 
flow during assistance of a fibrillating heart were reported to be 89 percent of normal 
values with coronary arterial flows ranging between 62 and 110 percent depending on the 
method of measurement. The myocardial oxygen consumption was shown to decrease 
from a normal level of 5.8 ml/min to 4.2 ml/min during total circulatory support with the 
device with the lactate levels in the coronary sinus decreasing or remaining unchanged. 
Some problems were associated with use of the Anstadt cup. Two related adverse 
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effects of the Anstadt device manifested as a banding effect of the ventricular sealing rim 
on the right ventricular outflow tract and histological lesions found in this same area of 
the heart after application of the device (Skinner et al., 1967). The banding effect of the 
right ventricular outflow tract did not significantly impede right ventricular outflow but 
did result in a pressure gradient between pulmonary arterial systolic pressures and right 
ventricular systolic pressures. Pathologic changes found in this area of the myocardium 
after variable periods of mechanical ventricular assistance included observable ecchymotic 
hemorrhage, microscopic evidence of myocardial necrosis, and eventual scar formation. 
These lesions were attributed to the rigidity of the external housing. Another pathological 
finding associated with use of the assist device was a diffuse epicarditis which manifested 
acutely as a fibrinous exudate and chronically as a layer of fiberous tissue which did not 
appear to be constricting. 
A potential problem with use of the Anstadt device arises because of the 
circumferential compression of the ventricles by the internal diaphragm during systole. 
This indiscriminate compression of the ventricles may interfere or disrupt coronary arterial 
bypass grafts if the device is used following these procedures. Also, because the 
performance of the Anstadt cup is dependent on an accurate fît with the heart and the 
outer casing of the device is rigid, numerous cups would need to be available to insure 
that the device could be utilized when needed. 
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CHAPTER 3. DESCRIPTION OF THE HEART CUFF 
Details of the design, development, construction, and initial testing of the direct 
systolic cardiac augmentation device, the heart cuff, which is being further evaluated in 
this current research project, have been previously described (Frake, 1992). A brief 
description of the device follows. 
The heart cuff is an external systolic mechanical ventricular assist device. It was 
designed to provide temporary partial-assistance for ventricular function during periods of 
postischemic myocardial dysfunction, thus avoiding any potential harmful effects resulting 
from excessive or prolonged use of inotropic stimulation or cardiopulmonary bypass. The 
heart cuff can also be r^idly applied and removed from any size heart without the 
extended surgery time and anticoagulant therapy required with LVAD use. 
The heart cuff consists of a thin, stainless steel band (0.005 in. thick) which is lined 
with an inflatable bladder made from 0.02 in. thick Silastic silicone rubber. The bladder 
is affixed to the band at multiple sites so that it will distend in a predetermined fashion 
when filled with saline. When this cuff is placed around the heart, the bladder is 
distended to assume approximately the diastolic shape of the ventricles and help fill the 
gap between the conical-shaped apex of the heart and the cylindrical shape of the device. 
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Proper filling of the bladder with saline is subjectively achieved by digital palpation and 
by maximizing peak systolic ventricular pressure development during assistance. This 
close fit between the bladder and the heart helps improve the efficiency of the balloons 
which provide the mechanical assistance to the ventricles by keeping them in close contact 
with the epicardial surface. 
Two inflatable balloons are positioned on the inside of the bladder such that each 
will be immediately adjacent to the free wall of one of the two ventricles when the device 
is in place. The balloons are made from two sheets of 0.01 in. thick Silastic silicone 
rubber. The sheets which are adjacent to the bladder of the device are Dacron reinforced 
to help direct the inflation of the balloons towards the ventricles. 
Inflation of the balloons was facilitated by the use of a Datascope System 83 intra-
aortic balloon pump (Datascope Corp., Paramus, NJ). The ECG signal used to 
synchronize balloon inflation with systole was acquired by introducing a catheter with four 
ECG electrodes at its tip into the left jugular vein and advancing the electrodes into a 
position near the right atrium. 
Sizing of the device to accommodate each individual heart is facilitated by Velcro 
strips which are attached to the outside of the stainless steel band. The strips allow the 
band to be fastened to itself with a variable amount of overlap which allows it to be fitted 
around hearts with different diameters. An illustration of the heart cuff is shown in Figure 
3.1. 
Two seperate mechanisms were fashioned to prevent the device from slipping 
towards the apex of the heart while the balloons are being alternately inflated and deflated 
in synchrony with systole and diastole, respectively. The first mechanism utilized a thin 
nylon skirt which extended from the proximal edge of the cuff. The nylon skirt 
incorporated a piece of umbilical tape which was snugged in purse-string fashion around 
the atrioventricular groove of the heart. An illustration of the heart cuff being held in 
position around the heart with the use of a nylon skirt and purse-string is shown in Figure 
3.2. The second mechanism involved tethering the cuff to the ascending aorta. After 
dissection, a ring was placed around the aorta. Two straps which extended from the aortic 
ring were then passed through rigid supports and fastened to the heart cuff. An 
illustration of the heart cuff being held in position around the heart with the use of an 
aortic ring is shown in Figure 3.3. The rigid supports were utilized to prevent the support 
straps from impinging upon the pulmonary artery and cranial (superior) vena cava. 
Figure 3.1: An illustration of the heart cuff with nylon skirt and purse-string 
Figure 3.2: An illustration of the heart cuff being held in position around the heart with 
the use of a nylon skirt and purse-string 
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Figure 3.3: An illustration of the heart cuff being held in position around the heart with 
the use of an aortic ring 
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CHAPTER 4. OBJECTIVES OF THE STUDY 
The main objective of this study was to determine if assistance with the heart cuff 
could significantly improve the hemodynamic parameters associated with a myocardium 
experiencing global postischemic myocardial dysfunction. In addition, regional function 
was assessed in an area of the left ventricular free wall to determine if mechanical 
assistance facilitated improvement in postischemic function. Based on an understanding 
that stunned myocardium retains a contractile reserve, it was believed that improvement in 
regional function of the stunned myocardium might be measurable during the partial 
assistance provided by the heart cuff. The heart cuff was also to be evaluated on whether 
or not it allowed an improvement of non-assisted cardiac function during a postischemic 
period of assist with the device. 
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CHAPTER S. EXPERIMENTAL MODEL 
The most commonly used model for myocardial stunning has been the occlusion of 
the left anterior descending coronary artery (LAD) in the dog for a period of less than IS 
minutes (Bolli, 1990a). This model has been shown to consistently result in prolonged 
contractile dysfunction without resulting in any myocardial tissue necrosis (Myers et al., 
1985). The rate of functional recovery after this reversible ischemia is primarily 
determined by the severity and duration of blood flow reduction during the period of 
ischemia. Because of considerable individual variability in the amount of collateral flow 
present during coronary occlusion in the dog, the rate of functional recovery of the 
myocardium is unpredictable for a given animal prior to temporary ligation (Bolli et al., 
1988b). Animals which exhibit hypokinesis or akinesis during ischemia have a very rapid 
recovery following reperfusion, and a more prolonged recovery is seen in animals which 
display dyskinesis during coronary occlusion (Bolli et al., 1988b). 
The high variability of collateral flow present among individual animals makes it 
very difficult to compare the functional recovery of one dog relative to that of another 
following coronary occlusions of similar duration (Bolli et al., 1988b), but that was not 
the problem with the use of this model in the current research. Each animal could be 
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used as its own control in the evaluation of the effects of the assist device. The problem 
with this model was that complete ligation of the LAD in the canine subject, although 
causing regional dysfunction of the myocardium, does not significantly affect any of the 
hemodynamic parameters commonly used to evaluate myocardial performance. The 
ability of the heart to compensate for the functional loss of a considerable amount of the 
myocardium was the reason that this experimental model would not be ideal for evaluation 
of the heart cuff. 
An experimental model which would more accurately simulate a clinical setting in 
which the heart cuff would be applied was necessary to show the full potential benefits of 
using the device. Intuitively, it is not difficult to believe that placement of the heart cuff 
might hinder normal cardiac function, especially with regard to the restriction of 
compliance and diastolic filling which would result in a decrease of cardiac output and 
force of contraction. To some extent the heart cuff does decrease normal cardiac 
performance (Frake, 1992), but the device was not intended to be used on a normal heart. 
It was designed to be used to partially assist myocardial tissue which had temporarily 
become severely dysfunctional secondary to transient ischemia. Ideally, the model used to 
evaluate the heart cuff would easily and consistently provide a postischemic heart which 
was severely dysfunctional but still maintained viable myocardium and full perfusion 
status. 
After a preliminary evaluation of the heart cuff, during which it was synchronized 
with a normal heart, temporaiy ligations were performed around various coronary arteries 
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to see what effect they would have on the hemodynamic aspects of the heart. These 
ligations were done in anticipation of finding an appropriate model for testing the device 
on a weakened heart. Staggered, multiple, temporary ligations of various coronary arteries 
do not provide a consistent model because of the tremendous collateral flow in some dogs, 
but one of the test animals fibrillated after approximately 12 minutes of ligation of the 
LAD. This heart fibrillated for about S or 6 minutes before it converted. During 
fibrillation assistance was given with both direct cardiac massage and with the heart cuff 
at a set rate of 75 beats per minute. After conversion, assistance with the heart cuff was 
synchronized with each contraction for 10 minutes. At this time the assistance with the 
device was switched to every other beat and data recordings were taken. 
The data that were recorded during this period clearly showed the beneficial effects 
of the assistance given by the heart cuff. There was a complete lack of systolic ejection 
from the left ventricle during non-assisted contractions. The ventricular pressure achieved 
by the myocardium was not sufficient to exceed the aortic pressure which had resulted 
from the immediately preceeding assisted contraction. The data also showed a significant 
improvement in myocardial contractility during assistance, both in the rate of pressure 
development, (dP/dt), and in segmental shortening during systole. This post-fibrillating 
myocardium serendipitously became a model for a globally stunned myocardium which 
could be used to evaluate the performance of the heart cuff in a situation similar to its 
intended use. 
This model is not without flaws. There are far too many unpredictable variables 
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involved with using a post-fibrillation heart for it to be consistent from one animal to the 
next. Consequently, each animal must serve as its own control. Also, because temporary 
fibrillation of the heart has apparently not been used as an experimental model for a 
globally stunned myocardium, the condition of the myocardium after 3 to S minutes of 
fibrillation in an anesthetised, open-chest canine subject has not been characterized. 
Therefore, some assumptions were made. 
It seems likely that a majority of the myocardium would be in a stunned state 
after S minutes of fibrillation without perfusion. Ventricular fibrillation induced by burst 
pacing in perfused, isolated ferret hearts was shown to have no adverse effects on 
intracellular pH, high-energy phosphates, or lactate efflux during twenty minutes of 
fibrillation when wall stresses were kept low enough to allow adequate perfusion 
(Koretsune and Marban, 1989). This finding seems to indicate that fibrillation does not 
metabolically overdemand myocardial tissue which is adequately perfused. The same 
study found that intracellular calcium increased to four times the normal level in 
myocardial tissue during nonischemic fibrillation and that after defibrillation these hearts 
speared to be stunned (Koretsune and Marban, 1989). A group of hearts was also 
fibrillated with higher wall stresses and ischemia present. The intracellular calcium levels 
in these hearts did increase dramatically above normal levels but did not appear to reach 
the levels found in the nonischemic fibrillating hearts. The rapid decrease in intracellular 
calcium after fibrillation and the postfibrillatoiy dysfunction were simular in both groups 
of hearts (Koretsune and Marban, 1989). 
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Because fibrillation does not appear to put an extreme metabolic demand on 
myocardial tissue, it seems unlikely that there would be an extreme metabolic difference 
between normal functioning and fibrillating myocardium after each becomes acutely 
ischemic. Increases in intracellular calcium levels during ischemia (Steenbergen et al., 
1987) are very similar to those found in fibrillating myocardium (Koretsune and Marban, 
1989), although they do not q)pear to occur as r*q)idly. These findings seem to indicate 
that fibrillation induced ischemia would be very similar to acute ischemia in normal 
functioning myocardium with the possible exception of a more rapid increase in 
intracellular calcium levels early during fibrillation. 
It is also conceivable that there may be scattered areas of both hibernating and 
ischemic myocardium present which would also contribute to the mechanical dysfunction 
noted after fibrillation. Additionally, because of subnormal arterial pressure, metabolic 
acidosis might also play an unknown role in the mechanical dysfunction of the post-
fibrillation heart. Again, even though a precise characterization of the state of the 
myocardium after fibrillation was not known and an unknown, variable influence of 
acidosis on myocardial contraction was likely present, this model could potentially provide 
a postischemic, globally-weakened myocardium which still retained full perfusion and, 
ideally, the ability to recover from the ischemic insult. This would allow the heart cuff to 
be evaluated on a postishemic heart which would resemble a clinical situation for which 
the device was intended to be used. 
Since the heart cuff was designed to provide only partial assistance in order to 
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decrease the wall stress of the ventricles to a functional threshold, any post-fibrillation 
myocardium which was not able to generate pressure within the left ventricle would not 
be a suitable model to evaluate the performance of the device. Conversely, because the 
evaluations were to be made over a period of one hour, any post-fibrillation myocardium 
which recovered too rapidly would also not be a suitable model. Therefore, animals 
which exhibited either of these behaviors were not included in the study. 
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CHAPTER 6. DATA ACQUISITION SYSTEM 
The data aquisition system used for these evaluations of the heart cuff has been 
previously described (Peckham, 1990). A brief description of the system, associated 
instrumentation, and their implementation in these studies follows. A computer- based 
oscillograph and data acquisition sytem (AT-Codas), Dataq Instruments, Inc., Akron, OH, 
was used with a Zenith Z-386-16 personal computer to acquire the data from the 
evaluations of the heart cuff. The host computer was equipped with an 80386 16 bit 
processor and an 80387-16 math coprocessor which ran at a clock rate of 16 MHz with 
zero wait states. One Mbyte of RAM, a 40 Mbyte hard disk, and dual floppy disks with 
1.2 Mbyte (5.25") and 1.44 Mbyte (3.5") capacity were available for memory, storage, and 
backup capabilities. 
AT-Codas 
The AT-Codas hardware and software system provided real time viewing of 1 to 
16 acquired waveforms on a VGA monitor with simultaneous storage using direct memory 
access to disk. This is available with a single keystroke command. Multiple channel 
display formats, both overlapping and nonoverlapping, are available in a smooth scroll 
waveform during real time display and in post acquisition. The analog-to-digital converter 
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(ADC) with this package is a successive-{q)proximation device with 12 bits of resolution 
(1 part in 4096) for 16 single ended or 8 differential channels. The input range for the 
ADC is +/- 2.5 V. The throughput rate for the system is programmable up to SO kHz. 
The system also includes a high performance input/output (I/O) module and an 
optional Advanced Codas computational software package. The I/O module buffers and 
multiplexes the analog input signals. Independent channel gains of 1, 2, S, 10, SO, 100, 
500, and 1000 times the input signal can also be selected with simple keystroke 
commands. Full range offset control (+/- 5.0 V) is available for each channel. The 
Advanced Codas computational software can calculate and generate scaled waveforms 
from previously acquired data through digital signal conditioning. Features available with 
this software include waveform differentiation, integration, moving average filtering, peak 
and valley capture, and rectification. Calculated channels are automatically calibrated 
with appropriate units and can be time-aligned and displayed simultaneously with 
previously recorded data channels. 
Six channels were used for each of the animals tested in this series of evaluations. 
Five single-ended channels were used to acquire the following waveforms; ECG, cardiac 
output, left ventricular pressure, aortic pressure, and central venous pressure. A 
differential channel was used to acquire the waveform of myocardial segmental shortening. 
A sampling rate of 250 Hz per channel was chosen for excellent signal resolution and 
maximization of convenient data storage capabilities. The highest signal frequencies 
encountered in the acquired data were the ECG signals with values near 100 Hz. The 
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selected sampling rate adequately reproduced the ECG signal. Improved resolution of this 
signal was not required as it was not to be analyzed. Also, a sampling rate of 250 Hz per 
channel allowed approximately 6.5 minutes of data to be stored in an 1170 kbyte file 
which could be conveniently stored on a single 1.2 Mbyte floppy disk. This file size was 
consistently sufficient for storing the amount of data acquired during a single evaluation of 
the heart cuff. 
The computer and each electrical device used for acquiring the various waveforms 
was powered up for at least thirty minutes prior to calibration to stabilize the temperature 
of all electrical components. 
ECG signal 
An intravenous catheter with four ECG electrodes was introduced into the left 
jugular vein and advanced into the vena cava near the right atrium in order to acquire an 
electrical signal from the myocardium. The catheter with electrodes was required because 
placement of the heart cuff consistently resulted in electrical isolation of the myocardium 
and an inability to acquire a surface ECG signal. Two of the electrodes were used to 
trigger balloon inflation and the signal from the remaining two electrodes was amplified 
with a Datascope 861 portable physiology scope and connected to the AT-Codas I/O 
module. 
Pressure transduction 
Vascular pressure signal transduction was accomplished using Millar MPC-500 
Mikro-Tip catheter pressure transducers (Millar Instruments, Inc., Houston, TX). The 
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pressure sensor for these units is an ultraminiature semiconductor strain gauge device 
which is side-mounted at the distal end of the catheter. These pressure transducers 
produce high fidelity pressure waveforms without the time delay and limited frequency 
response associated with fluid-filled pressure transduction systems. These characteristics 
become very important when a faithful determination of dP/dt is desired. The low mass 
of the silicon sensor also makes these transducers insensitive to acceleration forces and 
catheter whip artifacts. 
Millar model TCB-100 battery powered control units were used to supply bridge 
excitation, balance, and calibration control for each transducer. These units also supply 
signal amplification with a nominal output of 0.2 V/100 mmHg with a frequency response 
of dc to 8 kHz. Each control unit contains internal calibration output signals for electrical 
zero, 20 mmHg, and 100 mmHg. These electrical calibration signals were not used for 
calibration of the pressure transducers in this series of data recordings. A water 
manometer was used just prior to each evaluation to record pressure values of 0 mmHg 
and 20 mmHg for venous calibration and 0 mmHg and 75 mmHg for arterial and 
ventricular calibration. The pressure sensors were protected from light and soaked in 
sterile physiologic saline for at least thirty minutes prior to calibration. Each tranducer 
was routinely monitored for baseline drift and periodically checked for linearity. 
Cardiac output 
Cardiac output was monitored using a Transonic TIOID ultrasonic flowmeter 
(Transonic Systems Inc., Ithaca, NY). The Transonic flowmeter functions by alternately 
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passing a wide ultrasonic beam upstream and downstream through a vessel 
which is placed within the acoustic window of a perivascular flowprobe. The difference in 
transit-time between the two pathways of the wide beam is used to calculate the volume 
flow of the blood within the vessel. Any area within the acoustic window which is not 
occupied by the vessel will result in a zero difference of transit time between the two 
pathways of the ultrasonic beam. The proportion of the signal which records a zero 
transit time is used as a measurement of area and to calculate the volume flow. Output 
voltages range from zero to 1.0 volts nominal for flows from zero to the probe scale factor 
flow, respectively. Output filter settings of 0.1, 10, 30, and 100 Hz determine the low-
pass cut-off frequency of signals presented at the analog meter and the flow output 
connector. An output filter setting of 0.1 Hz provides an average flow output. 
A 12 mm or 16 mm perivascular flowprobe (model #12SB19S or #168572) was 
placed around the ascending aorta just distal to the aortic valve to measure the cardiac 
output. A precise fit is not essential for accuracy of the flowmeter, but the probe 
should not impinge on the vessel from which the measurements are being taken. Minimal 
dissection is required for accurate function of the flowprobe because the probe is factory 
calibrated for application on living vessels, but care should be taken to excise any fatty 
tissue which may interfere with the probe's acoustic pathway. A couplant is required to 
fill any empty space within the acoustic window to maintain an adequate ultrasonic signal 
between the two transducers across the full extent of the beam. H-R Lubricating Jelly 
(Carter Wallace, Inc., New York, NY) is a recommended couplant and was used in these 
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evaluations as needed. Prewarmed (37°C) sterile saline or blood may also be used. 
Before {q)plication, the probe was stabilized for 30 minutes in degassed physiological 
saline making sure that all air bubbles were dislodged from the probe surfaces during that 
time. The flowmeter was then zeroed and the measured zero output and a factory 
calibrated scale factor signal associated with the specific flowprobe being used were 
digitized, recorded and displayed with appropriate engineering units using AT-Codas. 
Cardiac segment length 
A Triton Technology Sonomicrometer 120 (Triton Technology, Inc., San Diego, 
CA) was used to assess length in a segment of the left ventricular free wall during each 
evaluation of the heart cuff. This device measures the transit-time between two small 
piezoelectric ceramic transducers which have been implanted into the myocardium. Its 
sampling rate is 1543 samples per second. The transit-time is then converted to an analog 
output voltage which is proportional to the distance between the transducers. The 
Sonomicrometer's DC output is adjustable from about 300 mv/mm to 3 volts/mm. 
Calibration of the device is accomplished by using an internal 1.58 MHz quartz clock 
which triggers an output pulse equivalent to distances in 1 mm increments (1 cycle equals 
1 mm). Calibration output signals of 0 mm and 20 mm were digitized, recorded, and 
displayed with appropriate engineering units using AT-Codas. 
Two ferroelectric ceramic transducers were placed into the myocardium (Freeman 
et al., 1985). The crystals were placed approximately 10 mm apart at mid-thickness into 
the left ventricular free wall near the center of and perpendicular to a line drawn between 
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the apex of the heart and the major branch of the left coronary artery. Placement of the 
crystals into the mid-thickness of the myocardium is important because the direction of the 
myocardial fibers is layered between the endocardium and the epicardium. 
Circumferential shortening occurs in the myocardial fibers located in the middle portion of 
the wall thickness. If the piezoelectric crystals are located in different myocardial layers, 
then translational or shearing motion may occur between the two crystals. This type of 
motion cannot be distinguished from axial displacement and will result in measurement 
error. 
Another source of measurement error may occur when a change in temperature 
alters the conduction velocity of sound in the tissue. The Sonomicrometer's readings are 
based on the velocity of sound in the medium in which the measurements are being taken 
being 1580 m/sec. The change in velocity with temperature in the physiological range is 
estimated to be approximately 0.1% per degree centigrade. Because the animals in this 
study were continuously warmed with a fluid heating pad and their body temperatures 
were monitored with an esophageal temperature probe throughout each evaluation, this 
mechanism should not have resulted in any significant relative error. 
The Sonomicrometer operates at a transmitted ultrasound frequency of S MHz. 
This frequency was chosen by the manufacturer as a good compromise frequency between 
resolution and attenuation in the 10 to 30 mm range for muscle. The limit of resolution is 
considered to be approximately one quarter wavelength which results in a theoretical 
resolution of approximately +/- 0.04 mm. A strong, consistent signal which has minimal 
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noise can be expected to have better resolution than +/- 0.04 mm if the trigger level is set 
low (just above noise level). Poorly aligned transducers with a weak, inconsistent signal 
and a high trigger level may result in cycle "jumps" by the trigger and measurement error. 
A single cycle jump corresponds to a 0.32 mm error in length. 
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CHAPTER 7. METHODS 
Animal preparation 
Thirteen mongrel dogs of either sex (weighing from IS.9 to 30 kg) were induced 
with thiamylal sodium (17.5 mg/kg), intubated, and anesthetized with 2% halothane and 
oxygen. A ventilator (delivering 15 ml/kg at 12 breaths per minute) was used following a 
left lateral thoracotomy at the sixth intercostal space. Lactated Ringers solution was 
administered via a catheter in the cephalic vein at a rate of 10 ml/kg/hr for the first hour 
and then at a rate of 5 ml/kg/hr until ventricular fibrillation was induced. Body 
temperature, measured via an esophageal probe, was maintained near 38° C with a heating 
pad beneath the animal. 
Following the thoracotomy, a pericardotomy incision was made ventral and parallel 
to the left phrenic nerve. The ascending aorta was then dissected free and a perivascular 
ultrasonic volume flowsensor (12 or 16 mm) was placed around it to measure cardiac 
output. A 2 - 3 cm segment of the right femoral artery and vein, the left common carotid 
artery, and the left jugular vein were then isolated. Heparin (50 units/kg) was then 
administered intravenously via the cephalic vein. 
Semiconductor pressure sensors were then introduced into the caudal vena cava, via 
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the right femoral vein, to record central venous pressure, into the proximal descending 
aorta, via the right femoral artery, to record aortic pressure, and into the left ventricle, via 
the left common carotid artery, to record left ventricular pressure. An ECG lead catheter 
was then introduced near the right atrium, via the left jugular vein, to facilitate 
synchronization of ventricular assistance with physiological systole. 
A pair of 5-MHz hemispherical piezoelectric ultrasonic crystals were implanted into 
the subendocardium of the mid-left ventricular free wall, approximately 10 mm apart and 
oriented parallel to the minor axis of the heart. These crystals were used to record 
segmental shortening in this region of the myocardium. 
All of the analog signals (central venous pressure, aortic pressure, left ventricular 
pressure, cardiac output, segmental shortening, and ECG) were digitized, displayed (real 
time), and recorded with a computer-based oscillograph and data acquisition system (AT-
Codas). Each channel was sampled at a rate of 250 samples per second. Waveforms 
displaying the rate of pressure change in the left ventricle (dP/dt), stroke volume, or LV 
pressure-segment length loops were each digitally generated post-acquisition. 
Baseline data were recorded after implantation of each component of the data-
aquisition system. After recording baseline data, a bolus of lidocaine (1.5 mg/kg) was 
given intravenously to the first eleven animals. Lidocaine is considered a class IB 
antiarrhythmic agent and was given as prophylaxis against reperfusion arrythmias (Preuss 
et al., 1987). Lidocaine has been given prophylactically prior to ischemia in other studies 
of myocardial stunning (Ciuffo et ai.; 1985, Krause and Hess; 1984, Ellis et ai., 1984; 
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Pruess et al., 1987). Because of the consistent negative inotropic effects seen on the heart 
after lidocaine administration in these studies, control data were recorded S minutes after 
the bolus injection of lidocaine. Baseline data were used as control data for animals 
which were not given a lidocaine bolus prior to fibrillation (Dogs 12 and 13). Each 
animal was given a continuous infusion of lidocaine (60 ^g/kg/min) which was initiated 
after the period of unassisted fibrillation and continued throughout the balance of the 
evaluation. The infusion of lidocaine was associated with a fluid administration rate of 60 
ml/hr (approximately 2.6 ml/kg/hr for each animal). 
Each heart was fibrillated by briefly introducing a low-voltage alternating current 
directly into the myocardium. The hearts were allowed to fibrillate unassisted for a period 
of 3 minutes (Dogs 8 - 13), 4.5 minutes (Dogs 2 - 7), or S minutes (Dog 1). Each heart 
was then massaged until defibrillation was achieved by delivering 30 or SO joules of 
energy to the ventricular myocardium. To prevent damage to any of the electronic 
equipment, the flow and pressure transducers were disconnected from their control units 
prior to defibrillation. 
After defibrillation, the heart cuff was rapidly placed around the ventricles and 
pressure and flow transducers were reconnected. Synchronized assistance was then 
initiated with each electrical systole for a duration of one hour. 
In order to compare cardiac performance with assistance versus without assistance, a 
10 second data recording was periodically taken during the every beat assistance. 
Immediately after recording data during every beat assistance, the assistance was 
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discontinued and another 10 second data recording was taken. When assistance was 
discontinued, the heart cuff was left in place, but the assist balloons were not inflated 
during systole. These data recordings allowed a direct comparison of the cardiac 
parameters with and without the mechanical assistance of the heart cuff. 
Because an evaluation was to be made on whether or not the non-assisted cardiac 
function improved during the postischemic assist period, comparison recordings were 
taken at S minute intervals during the hour long postischemic assist period. This interval 
allowed reasonably frequent updates of non-assisted cardiac function with minimal 
interruption of cardiac assistance. 
During trial uses of the heart cufT, augmentation of cardiac performance with every 
beat assistance had subjectively decreased when heart rates exceeded 130 beats per 
minute. This decrease in augmentation was believed to be due to an improper duration of 
ventricular filling. Because every other beat assistance with the heart cuff had resulted in 
more favorable cardiac parameters than every beat assistance when the heart rate was very 
rapid, it was decided to also evaluate cardiac performance during every other beat 
assistance with the heart cuff during thiâ study. Therefore, immediately after recording 
cardiac parameters during every beat assistance and then with no assistance, another 10 
second data recording was made during every other beat assistance with the device. After 
briefly recording cardiac performance during every beat assistance, no assistance and 
every other beat assistance, every beat assistance with the heart cuff was resumed until the 
next recording period. 
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Data analysis 
The data which were analyzed from six of the thirteen animals included the 
following parameters; left ventricular end-diastolic pressure (LVEDP), peak left 
ventricular pressure (LVP), maximum rate of change of LVP (dP/dt max), minimum rate 
of change of LVP (dP/dt min), stroke volume, end-diastolic length (EDL), end-systolic 
length (ESL), percent segmental shortening (SS), percent of control segmental shortening 
(SSpc), central venous pressure (CVP), mean arterial pressure (MAP) and mean cardiac 
output (MCO). 
Each measurement (except for CVP, MAP and MCO) was calculated by taking the 
average value from six individual cycles of a waveform during each specified data 
recording period. The values for CVP, MAP and MCO were mean values calculated from 
each sample taken during the entire specified data recording period. 
Each analyzed cycle of the LVP waveforms was edited by inserting an event marker 
at the data points corresponding to the LVEDP and peak LVP. An edited LVP waveform 
is shown in Figure 7.1. The time scale for each sample waveform in this chapter is 0.2 
seconds per division. The LVEDP was measured at the point of the initial large positive 
rise in the LVP waveform. 
An example of a segment length waveform is given in Figure 7.2. Each analyzed 
cycle of the segment length waveforms was edited by inserting an event marker at the 
data points corresponding to EDL and ESL. The EDL was measured at the point 
corresponding to the LVEDP event marker on the LVP waveform. The ESL was measured 
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at the point corresponding to the peak LVP event marker on the LVP waveform. The 
percent segmental shortening for each analyzed cycle was calculated as follows: 
SS = [(EDL - ESL)/EDL] X 100 
The percent of control segmental shortening was also calculated to normalize data due to 
differences in ultrasonic crystal distances between different animals. 
Examples of a cardiac output and stroke volume waveforms are shown in Figures 7.3 
and 7.4, respectively. The stroke volume waveform is a calculated waveform generated 
by integration of the cardiac output waveform in post-acquisition using AT-CODAS. The 
integral reset was set on zero crossings. The stroke volume waveform was edited by 
inserting an event marker at the maximum value of each integration. 
Examples of CVP and aortic pressure waveforms are given in Figures 7.S and 7.6, 
respectively. The mean values for these waveforms (and for cardiac output) were 
averages calculated from each data point recorded during a specified data recording 
period. 
An example of a waveform representing the rate of change in LVP is shown in 
Figure 7.7. The dP/dt waveform was calculated by digitally computing the first derivative 
of the LVP waveform in post-acquisition using AT-CODAS. The dP/dt waveform was 
edited by placing event markers at the maximum value (dP/dt max) and minimum value 
(dP/dt min) for each cycle. 
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Figure 7.7; A sample of a calculated dP/dt waveform with event markers showing dP/dt 
max and dP/dt min (Dog 3, control) 
CHAPTERS. RESULTS 
Data suitable for analysis were collected from six of the thirteen animals. Three 
dogs could not be defibrillated after the initial unassisted fibrillation. One dog fibrillated 
after 35 minutes of assistance and could not be defibrillated a second time. One dog 
fibrillated for greater than twenty minutes and never regained any cardiac function. One 
dog had a heart which was too large for the heart cuffs which were available. One dog 
fibrillated for 12 minutes and was assisted for 60 minutes post-fibrillation but the left 
ventricular pressure waveform showed excessive drift. Subjectively, the data for the latter 
dog most closely resembled that of Dog 6. 
The six animals from which data were analyzed fibrillated for varying amounts of 
time after the initial 3-5 minutes of unassisted fibrillation. Dog I fibrillated once for 35 
minutes (no assist (NA): 5 minutes; direct cardiac massage (DCM): 15 minutes; heart cuff 
assisted at 70 beats per minute (HCA): 15 minutes). Dog 2 fibrillated once for 7 minutes 
(NA: 4.5 minutes; DCM: 2.5 minutes). Dog 3 fibrillated once for 10 minutes (NA: 4.5 
minutes; DCM: 5.5 minutes). Dog 4 fibrillated once for 3 minutes (NA: 3 minutes). Dog 
5 fibrillated three times for a total of 19 minutes (NA; 3 minutes; DCM: 16 minutes). 
The durations of each fibrillation for Dog 5 were 6, 10 and 3 minutes. Synchronized 
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assistance with the heart cufif (BOB) between these fibrillations was performed for 20 and 
35 minutes. Dog 6 fibrillated once for S minutes (NA: 3 minutes; DCM; 2 minutes). 
Data used for analysis of the heart cuff was taken during a one hour period of continuous 
cardiac function without fibrillation after the aforementioned events for each of these six 
animals. 
Averages 
The following averages are total averages which were derived from data recorded 
during the entire period of postischemic synchronized assistance with the heart cuff for 
each animal. These data are shown in table form in Tables 8.1 - 8.4. Records for dogs 3, 
S and 6 with control, post-fibrillation (pf) and post-cuff off (pco) values are shown in 
Figures 8.1 - 8.33. LVEDP averaged 1S±2 and 16±3 mm Hg for every beat assist (EB) 
and no assist (NA), respectively. LVEDP averaged 17±3 and 16±3 mmHg for eveiy other 
beat assist during the assisted beat (EOB/A) and every other beat assist during the no 
assist beat (EOB/NA), respectively. Peak LVP averaged 56±7 and 27±8 mm Hg for EB 
and NA, respectively. Peak LVP averaged S8±7 and 28±10 mm Hg for EOB/A and 
EOB/NA, respectively. The maximum rate of change in left ventricular pressure (dP/dt 
max) averaged 441 ±107 and 164197 mm Hg per second for EB and NA, respectively. 
DP/dt max averaged 442±102 and 16S±101 mm Hg per second for EOB/A and EOB/NA, 
respectively. The minimum rate of change in left ventricular pressure (dP/dt min) 
averaged -362±67 and -128±72 mm Hg per second for EB and NA, respectively. DP/dt 
min averaged -380dh66 and -135±79 mm Hg per second for EOB/A and EOB/NA, 
Table 8.1: Averages and total averages during postischemic assist for 
LVEDP and Peak LV? 
Averages during postischenuc assist 
LVEDP (mmHg) Peak LVP (mmHg' 
eb na eob/a eob/na eb na eob/a eob/na 
Dog#l 17.12 16.03 18.17 16.36 50.82 18.82 52.99 21.27 
stdev 1.34 3.53 0.78 0.69 5.97 6.44 4.86 4.68 
Dog #2 15.13 17.74 18.20 18.09 55.28 40.59 73.18 36.91 
stdev 4.51 2.40 3.48 4.34 12.81 14.41 13.30 17.30 
Dog #3 14.40 16.42 15.63 15.34 58.48 25.11 56.01 26.83 
stdev 0.93 1.63 1.53 1.95 12.86 10.12 12.53 13.72 
Dog #4 12.41 14.56 15.77 12.99 63.47 23.02 62.99 22.08 
stdev 1.68 3.66 4.87 3.86 5.33 9.45 5.24 10.62 
Dog #5 13.79 14.09 14.67 13.30 49.34 19.43 44.12 23.74 
stdev 2.49 1.54 1.79 1.48 1.69 0.91 1.69 4.02 
Dog #6 18.28 18.04 18.80 18.15 60.18 33.52 57.42 38.15 
stdev 2.55 3.51 3.40 2.98 4.84 7.27 6.13 6.65 
Total averages during postischemic assist 
LVEDP (mmHg) Peak LVP (mmHg 
eb na eob/a eob/na eb na eob/a eob/na 
Average 15.19 16.15 16.87 15.71 56.26 26.75 57.79 28.16 
stdev 2.25 2.71 2.64 2.55 7.25 8.10 7.29 9.50 
Table 8.2: Averages and total averages during postischemic assist for dP/dt max, dP/t min and stroke volume 
Averages during postischemic assist 
dP/dt max (mmHg/sec) dP/dt min (mmHg/sec) Strvo (mis) 
eb na eob/a eob/na eb na eob/a eob/na eb na eob/a eob/na 
Dog #1 355.33 57.74 351.33 88.00 -320.47 -58.60 -340.37 -82.30 . 3.31 0.22 3.66 0.15 
stdev 89.83 55.96 84.79 53.63 27.29 65.54 36.83 61.34 0.13 0.26 0.24 0.11 
Dog #2 485.30 387.23 616.15 281.30 -313.07 -242.56 -457.85 -227.70 3.72 1.70 6.33 0.72 
stdev 197.14 212.00 209.19 211.44 117.64 125.48 103.96 143.38 1.19 0.81 0.57 0.85 
Dog #3 446.65 143.53 407.71 155.01 -336.36 -132.20 -334.71 -139.64 8.09 1.12 9.49 0.32 
stdev 155.24 110.89 150.34 120.73 118.92 95.06 111.82 103.68 1.85 0.93 1.76 0.49 
Dog #4 602.57 127.88 601.69 117.93 -460.58 -107.47 -444.99 -97.57 4.05 0.63 5.25 0.15 
stdev 87.55 77.67 77.08 78.54 55.48 53.51 72.57 59.36 0.62 0.65 0.59 0.38 
Dog #5 304.24 74.80 262.35 109.63 -337.13 -64.57 -303.52 -76.53 4.06 0.05 4.49 0.03 
stdev 33.39 31.04 23.84 51.21 28.75 23.89 32.65 31.52 0.78 0.06 0.62 0.05 
Dog #6 450.11 193.69 410.64 239.37 -403.85 -161.84 -400.77 -188.97 6.28 2.33 6.90 1.89 
stdev 79.82 94.02 66.94 90.83 56.74 68.67 37.97 73.01 1.57 0.74 0.82 0.88 
Total averages during postischemic assist 
dP/dt max (mmHg/sec) dP/dt min (mmHg/sec) Strvo l(mls) 
eb na eob/a eob/na eb na eob/a eob/na eb na eob/a eob/na 
Average 440.70 164.14 441.65 165.21 -361.91 -127.88 -380.37 -135.45 4.92 1.01 6.02 0.54 
stdev 107.16 96.93 102.03 101.06 67.47 72.02 65.96 78.71 1.02 0.57 0.77 0.46 
Table 8.3: Averages and total averages during postischemic assist for EDL, ESL and SS 
Averages during postischemic assist 
EDL (mm) • ESL( [mm) SS :%) 
eb na eob/a eob/na eb na eob/a eob/na eb na eob/a eob/na 
Dog #1 4.905 5.016 4.896 4.863 4.754 4.957 4.679 4.797 3.15 1.21 4.49 1.38 
stdev 0.196 0.237 0.170 0.167 0.277 0.304 0.292 0.216 2.10 1.42 2.69 1.11 
Dog #2 7.211 7.315 7.348 7.299 7.368 7.346 7.446 7.320 -2.17 -0.41 -1.33 -0.29 
stdev 0.188 0.115 0.133 0.164 0.267 0.131 0.155 0.191 2.40 0.86 1.68 0.95 
Dog #3 4.214 4.138 4.208 4.165 3.748 3.948 3.705 4.023 11.07 4.77 11.92 3.59 
stdev 0.402 0.374 0.381 0.380 0.358 0.465 0.318 0.460 1.42 2.67 1.82 2.39 
Dog #4 7.214 7.056 7.085 7.124 7.400 6.909 7.179 6.937 -2.60 2.10 -1.37 2.63 
stdev 0.140 0.210 0.237 0.201 0.031 0.268 0.457 0.228 1.66 1.11 6.36 1.40 
Dog #5 7.479 7.509 7.514 7.500 . 6.768 7.534 6.733 7.546 9.54 -0.33 10.40 -0.61 
stdev 0.091 0.077 0.084 0.087 0.208 0.088 0.188 0.120 1.70 0.19 1.54 0.48 
Dog #6 6.487 6.425 6.465 6.478 6.314 6.233 6.291 6.288 2.64 2.94 2.67 2.89 
stdev 0.414 0.446 0.437 0.432 0.406 0.417 0.410 0.4D1 2.26 2.22 1.96 2.40 
Total averages during postischendc assist 
EDL (mm) ESL [mm) SS (%) 
eb na eob/a eob/na eb na eob/a eob/na eb na eob/a eob/na 
Average 6.25 6.24 6.25 6.24 6.06 6.15 6.01 6.15 3.60 1.71 4.46 1.60 
stdev 0.24 0.24 0.24 0.24 0.26 0.28 0.30 0.27 1.93 1.41 2.67 1.45 
Table 8.4: Averages and total averages during postischemic assist for 
CVP, MAP and MCO 
Averages during postischemic assist 
CVP (mmHg) MAP (mm! tg) MCO(L/min) 
eb na eob eb na eob eb na eob 
Dog #1 10.83 11.60 11.05 30.30 15.22 25.69 0.16 0.01 0.11 
stdev 0.76 0.10 0.59 6.96 4.32 3.72 0.04 0.01 0.03 
Dog #2 13.92 13.62 12.86 33.70 29.69 42.45 0.33 0.21 0.41 
stdev 2.51 1.64 1.36 14.81 14.18 14.03 0.16 0.11 0.08 
Dog #3 11.92 12.90 12.19 39.97 22.65 33.11 0.56 0.07 0.35 
stdev 1.57 1.11 ,• 1.39 10.99 6.88 9.48 0.10 0.05 0.12 
Dog #4 10.43 11.97 10.83 44.09 14.91 35.23 0.49 0.09 0.37 
stdev 1.12 0.82 0.80 6.15 7.41 6.87 0.08 0.09 0.08 
Dog #5 10.00 10.13 10.01 31.03 16.19 23.00 0.58 0.08 0.31 
stdev 0.71 0.36 0.41 2.06 1.81 1.21 0.11 0.12 0.06 
Dog #6 11.89 12.49 11.98 39.43 24.79 32.44 0.49 0.22 0.37 
stdev 1.77 0.94 0.96 5.86 7.20 8.05 0.12 0.13 0.11 
Total averages during postischemic assist 
CVP (mmP [g) MAP (mm! ïg) MCO (L/min) 
eb na. eob eb na eob eb na eob 
Average 11.50 12.12 11.49 36.42 20.57 31.99 0.44 0.11 0.32 
stdev 1.41 0.83 0.92 7.81 6.97 7.23 0.10 0.08 0.08 
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Figure 8.1: Chart of LVEDP for an animal WUch showed gradual improvement in NA function 
during the postischemic assist period (Dog 3) 
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Figure 8.2: Chart of peak LVP for an animal vAiich showed gradual improvement in NA function 
during the postischemic assist period (Dog 3) 
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Figure 8.3: Chart of dP/dt max for an animal which showed gradual improvement in NA function 
during the postischemic assist period (Dog 3) 
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Figure 8.5: Chart of stroke volume for an animal which showed gradual improvement in NA 
function during the postischemic assist period (Dog 3) 
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Figure 8.6: Chart of EDL for an animal which showed gradual improvement in NA function 
during the postischemic assist period (Dog 3) 
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Figure 8.7: Chart of ESL for an animal vdiich showed gradual improvement in NA function 
during the postischemic assist period (Dog 3) 
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Figure 8.8: Chart of SS for an animal which showed gradual improvement in NA function during 
the postischemic assist period (Dog 3) 
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Figure 8.9: Chart of CVP for an animal v^ich showed gradual improvement in NA function 
during the postischemic assist period (Dog 3) 
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during the postischemic assist period (Dog 3) 
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Figure 8.11: Chart of MCO for an animal which showed gradual improvement in NA function 
during the postischemic assist period (Dog 3) 
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Figure 8.12: Chart of LVEDP for an animal which showed r^id improvement and gradual decline 
in NA function during the postischemic assist period (Dog 6) 
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Figure 8.13: Chart of peak LVP for an animal Wiich showed rapid improvement and gradual 
decline in NA function during the postischemic assist period (Dog 6) 
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Figure 8.14: Chart of dP/dt max for an animal Wiich showed rapid improvement and gradual 
decline in NA function during the postischemic assist period (Dog 6) 
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Figure 8.15: Chart of dP/dt min for an animal which showed r:q>id improvement and gradual 
decline in NA function during the postischemic assist period (Dog 6) 
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Figure 8.16; Chart of stroke volume for an animal which showed r^id improvement and gradual 
decline in NA function during the postischemic assist period (Dog 6) 
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Figure 8.17: Chart of EDL for an animal \^diich showed rapid improvement and gradual decline in 
NA function during the postischemic assist period (Dog 6) 
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Figure 8.18: Chart of ESL for an animal which showed r^id improvement and gradual decline in 
NA function during the postischemic assist period (Dog 6) 
SS DOG #6 
12 T 
1 0  • •  
c 
8 
& 4-
2 • 
Q. CL Q. 
C 
S o in o lO in m U) in CO o in CO 
time 
CM in 
•— eb 
- na 
•— eob/a 
0— eob/na 
*— cuff off 
Figure 8.19: Chart of SS for an animal which showed r^id improvement and gradual decline in 
NA function during the postischemic assist period (Dog 6) 
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Figure 8.20: Chart of CVP for an animal which showed ri^id improvement and gradual decline in 
NA function during the postischemic assist period (Dog 6) 
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Figure 8.21: Chart of MAP for an animal w^ich showed r2q>id improvement and gradual decline in 
NA function during the postischemic assist period (Dog 6) 
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Figure 8.22: Chart of MCO for an animal w^ich showed rq)id improvement and gradual decline in 
NA function during the postischemic assist period (Dog 6) 
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Figure 8.23: Chart of LVEDP for an animal which showed neitiier improvement or decline in NA 
function during the postischemic assist period (Dog S) 
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Figure 8.24: Chart of peak LVP for an animal i^ich showed neither improvemoit or decline in NA 
function during the postischemic assist period (Dog S) 
dP/dt max DOG #5 
1200 J 
1000 I 
800 • 
600 • 
a. *5. *5. *S. Q. Q. Q. Q. Q. cL Q- Q- Q. 
c 
.5 c c .5 C C c C c C c c 
E E E E E E E E E E E E E 
m o lO o m ' o m o o m o CM CM CO CO to U) <o 
time 
•— eb 
- na 
#— eob/a 
0— eob/na 
A— cuff off 
Figure 8.25: Chart of dP/dt max for an animal which showed neither improvement or decline in NA 
function during the postischemic assist period (Dog 5) 
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Figure 8.26: Chart of dP/dt min for an animal which showed neither improvement or decline in NA 
function during the postischemic assist period (Dog 5) 
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Figure 8.27: Chart of stroke volume for an animal wdiich showed neither improvement or decline in 
NA function during the postischemic assist period (Dog S) 
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Figure 8.28: Chart of EDL for an animal wdiich showed neidier improvement or decline in NA 
function during the postischemic assist period (Dog S) 
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Figure 8.29; Chart of ESL for an animal ^ch showed neiAer improvement or decline in NA 
function during the postischemic assist period (Dog 5) 
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Figure 8.30: Chart of SS for an animal which showed neiAer improvement or decline in NA 
function during the postischemic assist period (Dog S) 
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Figure 8.31: Chart of CVP for an animal which showed neiAer improvement or decline in NA 
function during tfie postischemic assist period (Dog S) 
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Figure 8.32: Chart of MAP for an animal vdiich showed neither improvement or decline in NA 
function during the postischemic assist period (Dog S) 
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Figure 8.33: Chart of MCO for an animal which showed neither improvement or decline in NA 
function during the postischemic assist period (Dog 5) 
Table 8.5: Control values and averages 
Contro values 
LVEDP PeakLVP dP/dtmax dP/dtmin Sir vol EDL ESL ssr/o) CVP MAP MCO 
Dog#l 10.94 83.18 828.67 -1081.67 10.29 10.150 9.385 7.54 4.13 70.03 1.22 
stdev 0.25 0.69 12.56 11.69 0.29 0.055 0.038 0.28 0.59 5.34 1.56 
Dog #2 11.97 74.73 672.33 -661.50 7.94 7.978 6.912 13.36 5.95 44.60 0.74 
stdev 1.20 0.55 8.21 12.97 0.33 0.027 0.048 0.82 0.48 7.52 1.23 
Dog #3 10.24 69.47 570.00 -700.67 11.74 5.392 4.475 17.00 9.13 57.90 1.03 
stdev 0.67 0.86 18.31 12.04 0.11 0.022 0.034 0.73 0.35 5.05 1.84 
Dog #4 14.88 86.65 831.05 -1001.37 7.39 5.751 5.798 -0.82 6.66 72.04 0.91 
stdev 0.83 0.51 11.68 20.72 0.35 0.020 0.014 0.31 0.45 4.97 1.36 
Dog #5 3.70 85.80 1080.00 -1481.67 15.32 10.000 9.098 9.02 7.68 68.70 1.87 
stdev 0.60 1.06 44.72 34.88 1.00 0.092 0.048 0.70 0.26 7.62 3.10 
Dog #6 9.28 91.12 1077.33 -1110.67 8.89 6.453 5.888 8.76 10.73 80.58 1.07 
stdev 0.60 0.39 17.06 13.98 0.16 0.023 0.027 0.33 0.12 7.04 0.08 
Control averages 
Total 10.17 81.83 843.23 -1006.26 10.26 7.621 6.926 9.14 7.38 65.64 1.14 
stdev 3.71 8.13 207.41 301.62 2.94 2.098 1.956 6.03 2.35 12.61 0.39 
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respectively. Stroke volume averaged S±1 and 1±1 ml for EB and NA, respectively. 
Stroke volume averaged 6±1 and 1±1 ml for EOB/A and EOB/NA, respectively. End 
diastolic length (EDL) averaged 6.2S±0.24 and 6.24±0.24 mm for EB and NA, 
respectively. EDL averaged 6.2S±0.24 and 6.24±0.24 mm for EOB/A and EOB/NA, 
respectively. End systolic length (ESL) averaged 6.06±0.26 and 6.1S±0.28 mm for EB 
and NA, respectively. ESL averaged 6.0110.30 and 6.1510.27 mm for EOB/A and 
EOB/NA, respectively. Segmental shortening (SS) averaged 3.6±1.9 and 1.7±1.4 percent 
for EB and NA, respectively. SS averaged 4.S±2.7 and 1.6±1.S percent for EOB/A and 
EOB/NA, respectively. The percent of control for segmental shortening (SSpc) averaged • 
1S±S0 and S4±34 for EB and NA, respectively. SSpc averaged 16±146 and 64±40 for 
EOB/A and EOB/NA, respectively. Central venous pressure (CVP) averaged 12±1, 12±1 
and 11 ±1 mm Hg for EB, NA and EOB, respectively. Mean arterial pressure (MAP) 
averaged 36±8, 21±7 and 32±7 mm Hg for EB, NA, and EOB, respectively. Mean 
cardiac output (MCO) averaged 440±100, 110±80 and 320±80 ml per minute for EB, NA, 
and EOB, respectively. 
Trends 
The total averages for LVEDP for each method of assist after defibrillation were 
greater than the average control value. See Table 8.5. There was a slight tendency for 
the LVEDP to be less during EB and EOB/NA (149% and 154% of control, respectively) 
than during NA and EOB/A (159% and 166% of control, respectively). 
The total averages for peak LVP for each method of assist after defibrillation were 
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less than the average control value. There was a strong tendency for the peak LVP to be 
greater during EB and EOB/A (69% and 71% of control, respectively) than during NA 
and EOB/NA (33% and 34% of control, respectively). Three dogs showed a gradual 
improvement in NA peak LVP development throughout the assisted postischemic period, 
improving from 12±0.4 to 27±0.4 mm Hg (Dog 1), 14±1.1 to 43±1.0 mm Hg (Dog 2) and 
13±0.9 to 41±0.8 mm Hg (Dog 3). See Figure 8.2. Two dogs improved in NA peak 
LVP development during the first ten minutes of assistance going from 23±0.2 to 43±0.3 
mm Hg (Dog 4) and 32±0.S to S0±0.9 mm Hg (Dog 6). See Figure 8.13. The NA peak 
LVP in these two dogs then gradually decreased to initial postischemic values over a 
fifteen minute period and remained at approximately these levels during the remainder of 
assistance. One dog (Dog S) maintained at the initial postischemic NA peak LVP values 
throughout the entire period of assistance (from 20±0.1 to 21±1.7 mm Hg). See Figure 
8.24. 
The total averages for each method of assist after defibrillation for dP/dt max were 
less than the average control value. There was a strong tendency for the dP/dt max to be 
greater during EB and EOB/A (52% of control for each) than during NA or EOB/NA 
(19% and 20% of control, respectively). Improvement of NA dP/dt max values 
throughout the assisted postischemic period followed patterns similar to those found with 
NA peak LVP development. 
The total averages for each method of assist after defibrillation for dP/dt min were 
less than the average control value. There was a strong tendency for the dP/dt min to be 
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greater during EB and EOB/A (36% and 38% of control, respectively) than during NA 
and EOB/NA (13% and 13% of control, respectively). The progression of NA dP/dt min 
values throughout the assisted postischemic period followed patterns similar to those found 
with NA peak LVP development. 
The total averages for each method of assist after defibrillation for stroke volume 
were less than the average control value. There was a strong tendency for the stroke 
volume to be greater during EB and EOB/A (48% and 58% of control, respectively) than 
during NA and EOB/NA (10% and S% of control, respectively). The progression of NA 
stroke volume values throughout the assisted postischemic period followed patterns similar 
to those found with NA peak LVP development. 
The total averages for each method of assist after defibrillation for EDL were less 
than the average control value. There was no overall tendency for the EDL to be greater 
during any particular method of assist. The average EDL during the entire postischemic 
assist period for each method of assist was 82% of the average control value. 
The post-defibrillation values for EDL decreased from control values for three of 
the animals (Dogs 2, 3 and S). The initial decreases in EDL went from 7.98 mm to an 
average of 7.62 mm for each method of assist (Dog 2), from 5.39 mm to 4.97 mm (Dog 
3, Figure 8.6) and from 10.00 mm to 7.36 mm (Dog 5, Figure 8.28). After the initial 
decrease in EDL, two of the animals (Dogs 2 and 3) showed a slow decrease in average 
EDL throughout the postischemic assist period with the final averages being 7.25 mm 
(Dog 2) and 4.29 mm (Dog 3). After the initial decrease, Dog S showed a slow increase 
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in EDL throughout the assist period with the final average being 7.62 mm. 
The post-defibrillation values for EDL increased from control values for two of the 
animals (Dogs 4 and 6). See Figure 8.17. The initial increases in EDL went from 5.75 
mm to an average of 7.52 mm for each method of assist (Dog 4) and from 6.45 mm to 
7.37 mm (Dog 6). After the initial increase in EDL, each of these animals showed a slow 
decrease in EDL throughout the postischemic assist period with the final averages being 
7.10 mm (Dog 4) and 6.12 mm (Dog 6). 
The sonomicrometer crystals for Dog 1 needed to be repositioned between the time 
of control recordings and post-fibrillation. The EDL slowly decreased in this animal 
during the postischemic assist period from an initial average of 5.20 mm to a final average 
of 4.71 mm. 
The total averages for each method of assist after defibrillation for ESL were less 
than the average control value. There was a slight tendency for the ESL to be less during 
EB and EOB/A (87% of the average control for each) than during NA and EOB/NA (89% 
of the average control for each). 
The total averages for each method of assist after defibrillation for segmental 
shortening were less than the average control value. There was a tendency for the 
segmental shortening to be greater during EB and EOB/A (40% and 49% of control, 
respectively) than during NA and EOB/NA (19% and 18% of control, respectively). 
The total averages for CVP for each method of assist during the postischemic 
assist period were greater than the average control value. There was a slight tendency for 
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the CVP to be less during EB and BOB (155% of control for each) than during NA 
(164% of control). 
The total averages for MAP for each method of assist during the postischemic 
assist period were less than the average control value. There was a tendency for the MAP 
to be greater during EB and BOB (55% and 49% of control, respectively) than during NA 
(31% of control). 
The total averages for MCO for each method of assist during the postischemic 
assist period were less than the average control value. There was a tendency for the MCO 
to be greater during EB and EOB (39% and 28% of control, respectively) than during NA 
(10% of control). 
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CHAPTER 9. DISCUSSION 
Experimental model 
There were problems associated with the globally postischemic heart model that 
was used to evaluate the performance of the heart cuff in these experiments. The first 
difficulty with the model was in reproducibility. Only 7 of 13 animals (54%) were able to 
be successfully defîbrillated and then assisted for a continuous 1 hour period. No two 
animals fibrillated for the same duration of time. Four of the animals either could not be 
defîbrillated or fibrillated for extended periods of time. Because of these problems, the 
postischemic model did evolve slightly during this series of evaluations of the heart cuff 
The initial animal in the study was given a bolus of lidocaine (1.5 mg/kg), was allowed to 
fibrillate unassisted for 5 minutes and was then given direct cardiac massage (while 
initiating a 60 ^g/kg/min intravenous lidocaine drip) for a duration of time which had not 
been predetermined before defibrillation was attempted. The final two animals in the 
study were not given a bolus of lidocaine before fibrillation. This decision was made 
because it was suspected that the distinct decrease in cardiac performance that was 
associated with the administration of the lidocaine bolus in previous animals may have 
had an additional adverse effect on the performance of the postischemic myocardium. The 
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last two dogs were allowed to fibrillate unassisted for 3 minutes after which time the 60 
Hg/kg/min intravenous lidocaine drip was initiated with a 2 minute period of direct cardiac 
masssage before defibrillation was attempted. Although one of these final two animals 
(Dog S) did fibrillate again during postischemic assistance, the final method used to 
produce a model of a globally postischemic heart seemed to be more reliable for obtaining 
a functional heart after defibrillation than those previously used. 
The second problem with the heart model was that assumptions had to be made 
regarding the state of the myocardium at the time of initiation of assist with the heart cuff. 
The primary assumption was that the majority of the myocardium would be stunned after 
defibrillation. This assumption was made because each of the hearts in the study had 
fibrillated unassisted for less than 10 minutes. Whether or not scattered areas of 
hibernating or ischemic myocardium developed in any of the hearts was not determined. 
The duration of unassisted fibrillation appeared to make a large difference in 
postischemic cardiac performance and recovery. Three of the six animals from which data 
were analyzed (Dogs 1, 2 and 3) fibrillated a single time and had unassisted periods of 
fibrillation which lasted longer than 4.5 minutes. Each of these animals had initial NA 
peak LVP values which were less than IS mm Hg, and each showed a gradual 
improvement in cardiac performance during the postischemic assist period. Dog 2 reached 
a maximum NA peak LVP value of 55 mm Hg at 30 minutes post-defibrillation at which 
time the cuff was briefly removed to compare NA values with values when the heart cuff 
was removed from the animal. The NA peak LVP values did decrease slightly after the 
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cuff was replaced (at approximately 33 minutes post-defibrillation). The series of charts 
for each measured parameter for Dog 3, shown in Figures 8.1 - 8.11, is representative of 
the gradual improvement in NA cardiac function during the postischemic assist period 
seen with Dogs 1, 2 and 3. 
Two of the six animals from which the data were analysed (Dogs 4 and 6) 
fibrillated a single time and had unassisted periods of fibrillation Wiich lasted only 3 
minutes. Each of these animals had initial NA peak LVP values greater than 23 mm Hg, 
and each recovered r^idly during the postischemic assist period. Maximum NA peak 
LVP values for both of these animals were greater than 44 mm Hg and were reached at 
10 minutes post-defibrillation. The NA peak LVP values then steadily decreased during 
the rest of the postischemic assist period for each of these animals. The series of charts 
for each measured parameter for Dog 6, shown in Figures 8.12 - 8.22, is representative of 
the rapid improvement and gradual decline in NA cardiac function during the postischemic 
assist period seen with Dogs 4 and 6. 
One of the animals (Dog 5) initially fibrillated unassisted for only 3 minutes (as 
did Dogs 4 and 6), but during the first 55 minutes of postischemic assistance this animal 
fibrillated two more times. The NA performance of Dog 5 remained essentially constant 
throughout the hour long assistance with the heart cuff which followed these fibrillations 
with NA peak LVP continuously being near 20 mm Hg. A series of charts for each 
measured parameter for Dog 5 is shown in Figures 8.23 - 8.33. 
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Performance of the heart cuff 
The heart cuff was quickly and easily positioned around the heart during each 
application. The purse-string mechanism successfully prevented the device from being 
ejected off the ventricles for the entire duration of assist every time the heart cuff was 
placed around the heart. Tethering the device to a ring around the ascending aorta was 
not evaluated during the current study because this position was occupied by a flow probe. 
The performance of the heart cuff in regard to improvement in cardiac parameters 
will be described in terms of percent change during every beat assist relative to no assist 
because the device was intended to be used to augment each heartbeat. The percent 
change in cardiac function between every beat assistance with the heart cuff and no 
assistance will be an average from all six animals during each postischemic assist period 
and will be given with the standard error of the mean. A brief description of the cardiac 
performance during every other beat assistance with the heart cuff will follow the 
comparison of every beat assistance relative to no assistance with the device. 
It is important to keep in mind that an extremely large percent improvement in any 
given cardiac parameter during assistance with the device relative to non-assisted function 
is more likely a reflection of the severity of the cardiac dysfunction without assistance 
than a true reflection of the augmentation capabilities of the device. To keep the percent 
improvements in cardiac function during every beat assist relative to no assist in 
perspective, the reader should refer to Tables 8.1 - 8.4 (pages SO - S3) and the data 
recorded during every beat assistance (eb) relative to no assistance (na). 
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Assistance with the heart cuff improved the performance of the postischemic hearts 
in this study for each of the cardiac parameters which was evaluated. The LVEDP 
decreased by an average of 6.0 ± 1.5% during every beat assist relative to no assist. Peak 
LVP increased by an average of 124 ± 9% during every beat assist relative to no assist. 
Maximum dP/dt increased by an average of 260 ± 29%, and the minimum dP/dt decreased 
by an average of 255 ± 28% during every beat assist relative to no assist. Stroke volume 
increased by an average of 1813 ±513% during every beat assist relative to no assist. 
EDL increased by an average of 0.18 ± 0.30%, and ESL decreased by an average of 1.8 ± 
1.0% during every beat assist relative to no assist. Percent segmental shortening increased 
by an average of 436 ±212% during every beat assist relative to no assist. CVP 
decreased by an average of 5.2 ± 0.9% during every beat assist relative to no assist. 
MAP increased by an average of 89 ±10%, and MCO increased by an average of 575 ± 
87% during every beat assist relative to no assist. 
Besides enhancing cardiac function, the heart cuff appeared to also allow the 
postischemic myocardium to partially recover from functional losses attributable to 
temporary ischemia. Assistance with the heart cuff during the postischemic period 
resulted in a gradual improvement in NA cardiac function in three animals (Dogs 1, 2 and 
3). The device maintained NA cardiac performance during the postischemic period in a 
dog which may not have had the capacity to improve (Dog 5). 
In the two animals which seemingly had the highest likelihood of showing a 
gradual improvement in NA cardiac performance during the postischemic assist period 
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(Dogs 4 and 6), assistance with the heart cuff resulted in an early, rapid rise in NA 
function which was followed by a gradual decrease in NA performance. A possible 
explanation for this may be that the device was physically restricting the return to normal 
cardiac function. 
The heart cuff has been previously shown to decrease cardiac function when placed 
on a normal functioning heart in an anesthetized dog (Frake, 1992). This study found the 
peak LVP to decrease by an average of 20.7 ± 3.0% and the stroke volume to decrease by 
an average of 36.5 ± 5.4% when the device was placed on the heart and the bladder 
pressurized. Physical restriction of cardiac function may have placed an added burden on 
the weakened hearts which were rq)idly attempting to resume normal function in the 
current study (Dogs 4 and 6). Rather than quickly returning to normal function, these 
hearts may have been forced back to a lower state of functional equilibrium by the 
presence of the heart cuff. 
If physical restriction of function by the heart cuff was responsible for the lack of 
continued improvement in NA function during the postischemic period for Dogs 4 and 6, 
then it would appear that this restriction was less critical with hearts that were more 
severely dysfunctional (Dogs 1, 2, and 3). Because of this mechanical restriction, use of 
the heart cuff as currently designed would be limited to only severely dysfunctional hearts. 
As a stunned heart gradually improved in function, there would be an ill-defined point at 
which continued use of the device would be detrimental to the continued recovery of the 
heart. Ideally, the presence of the heart cuff would not be detrimental to cardiac function 
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regardless of myocardial state. 
Design improvements could help decrease the amount of physical restriction which 
the heart cuff imposes upon a functioning heart. The heart cuff was designed with a 
maximum volume of 34 ml available from the intra-aortic balloon pump to inflate the 
assist balloons adjacent to the heart. Because of this the heart cuff had to be designed to 
efficiently use a minimal amount of available balloon volume to assist the heart during 
qrstole. A device which is less restrictive to normal cardiac function may be feasible with 
the use of a larger balloon volume. Also, the use of light-weight, non-distensible, flexible, 
non-metal materials for the outer shell may improve the design by making it less 
restrictive to cardiac function. 
A brief description of cardiac function during every other beat assistance will now 
be given. The reader is again referred to Tables 8.1 - 8.4 (pages SO - 54) and data 
recorded with every other beat assistance during the assisted beat (eob/a) and the non-
assisted beat (eob/na). 
The cardiac performance during eob/a and eob/na fairly closely paralleled that 
recorded during eb and na, respectively, for the following parameters: LVEDP, peak 
LVP, dP/dt max, dP/dt min, stroke volume, EDL, ESL, and percent segmental shortening. 
Any differences in these comparisons may have been due in part to the Frank-Starling 
law, which states that stretched muscle contracts with increased force. Poor ventricular 
ejection during an eob/na systole would tend to preload the ventricle with a larger volume 
of blood for the subsequent eob/a systole relative to the ventricular filling which would 
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occur during every beat assistance. Thus, cardiac performance with these parameters 
would be expected to be slightly increased during eob/a when compared to every beat 
assistance. Conversely, a similar argument could be given to explain a slight decrease in 
performance during eob/na when compared to no assistance. In regard to systemic 
parameters, there was little differece between CVP during eb, na, and eob assistance. 
MAP and MCO, although improved during eob assist relative to na, had a tendency to be 
decreased during eob assistance relative to every beat assistance. 
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CHAPTER 10. CONCLUSIONS 
A direct systolic cardiac augmentation device, the heart cuff, was developed and its 
performance was evaluated on canine hearts during global postischemic dysfunction. The 
device was quickly, easily, and securely positioned around hearts of varying size for the 
duration of the study. 
The experimental model used in this study involved temporary, normothermic, 
global ischemia due to electrically induced ventricular fibrillation. The model was very 
difficult to consistently reproduce but did allow the performance of the heart cuff to be 
evaluated under experimental conditions which seemingly resembled the clinical situations 
for which the device was intended. None of the experimental models created in this study 
was able to support life during the postischemic period without some sort of assistance. 
The assistence provided by the heart cuff was found to consistently improve the 
hemodynamic parameters associated with a canine heart during global postischemic 
dysfunction. Assistence with the heart cuff was also found to enable improvement in the 
mechanical performance of a segment of the postischemic left ventricular free wall. An 
inconsistancy in displaying an improvement in segmental shortening during assistance may 
have been due to improper transducer placement from either poor positioning or traumatic 
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introduction into the myocardium. The state of the myocardium and the metabolic state of 
the animal may have also had an effect on cardiac segmental shortening in this study. 
In addition to the enhancement of cardiac performance, a gradual improvement in 
non-assisted cardiac function was seen in three of six animals during use of the device for 
a one hour postischemic period. Non-assisted cardiac function was maintained during the 
postischemic period in one animal which fibrillated numerous times and may not have had 
the capacity to improve. 
Two animals in the study had the highest likelihood of showing improvement in 
non-assisted function during the postischemic assist period because of their shorter 
duration of ischemia. These two animals showed a r^id, early increase in non-assisted 
cardiac function which was followed by a gradual decrease in and then maintenance of 
function during postischemic assist with the device. The heart cuff has been previously 
shown to decrease cardiac function when placed on a normal heart and physical restriction 
of the heart by the device may have been why the two hearts with the shortest periods of 
ischemia did not return to normal function with the device in place. Because this 
response was not seen during postischemic assist with hearts that had longer periods of 
ischemia, use of the heart cuff as currently designed may be limited to only severely 
dysfunctional hearts. 
The heart cuff was shown to significantly enhance the cardiac performance of 
postischemic dysfunctional hearts in this study. The device was also shown to allow 
improvement in non-assisted cardiac function in more severely dysfunctional hearts during 
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an hour long postischemic assist period. With previous studies of similar assist devices 
showing only minimal myocardial damage, use of the heart cuff appears to be a feasible 
means of providing safe, easy, rapid and reliable assistance to postischemic, severely 
dysfunctional hearts. 
Because the current design of the device is restrictive to normal cardiac function, 
its application seems to be limited to temporaiy use on severely dysfunctional hearts. As 
these hearts recovered there would appear to be a point where further use of the heart cuff 
would be detrimental to the restoration of full cardiac function. Design improvements 
which might broaden the applicability of the heart cuff include enlarging the volume of air 
delivered to the assist balloons and the use of lightweight, flexible, non-distensible, non-
metal materials for the outer shell of the device. 
Possibly because of current design limitations, especially in regard to the volume 
of air delivered to the assist balloons, we were unable to assist the globally postischemic 
hearts to return to a state at which they could adequately maintain hemodynamic 
parameters which were compatible with life without cardiac support. The use of an open-
chest, anesthetized subject may also have been detrimental to achieving a postischemic 
myocardium which could again maintain normal hemodynamic parameters without 
assistance, as these subjects seem more likely to degrade with time than a closed-chest, 
conscious subject. After design improvements have been made, further studies could be 
performed to evaluate whether the device could assist a globally postischemic myocardium 
to return to a normally functioning state. With a reproducible model, comparisons could 
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also be made between postischemic recovery with mechanical support using the heart cuff 
versus pharmacological support using positive inotropes. 
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